Ryzneuta is a novel dimeric G- CSF long-acting fusion protein without pegylation. The Biologics License Application (BLA) of Ryzneuta is currently under late-stage review by the US FDA for Chemotherapy-Induced Neutropenia (CIN)
Ayush market has reached US $18 billion from meager US $3 billion under guidance and visionary leadership of our Prime Minister
Reinforcing GLC’s commitment to sustainable processing in pharmaceutical chemistry
Viehbacher brings extensive international experience in large pharmaceutical and entrepreneurial biotech companies
Doxycycline Capsules (RLD Oracea) had estimated annual sales of US $215 million in the US
Drospirenone Tablets (RLD Slynd) had estimated annual sales of US $141 million in the US
Innovative Capsugel Enprotect capsule can simplify the manufacturing process to accelerate drug development and expedite first-in-human timelines
Through the collaboration, Lonza will gain access to Singzyme’s enzymatic conjugation platform enabling the site-specific binding of payloads with peptidic linkers to proteins of interest
The company has been ranked 8th on the list this year for three key attributes: ‘innovative leader in the industry’, ‘is socially responsible’ and ‘has loyal employees’
The company is committed to addressing the observations at the earliest, and gaining approval for injectable manufacturing for the US
Subscribe To Our Newsletter & Stay Updated
